Lupus & antiphospholipid syndrome
Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III‐D Report: Multicriteria Decision Analysis
Authors' conclusion
Using MCDA, candidate criteria preliminary weights were determined. Unlike other disease classification systems using a single-aggregate threshold score, separate clinical and laboratory domain thresholds were incorporated into the new APS classification criteria.
Study context
- Population
- International real-world patients referred for "suspected antiphospholipid syndrome (APS)" with a wide range of APS manifestations20 representative patients ranked
- Participants
- 192 patients
- Outcome
- Relative weights of candidate criteria and an APS classification threshold score
Methodological detailsmulticriteria decision analysis, consensus-based, 1000Minds software, international, Phase I and II resulted in 27 proposed candidate criteria in laboratory and clinical domains
- Multicriteria decision analysis
- Consensus-based
- 1000Minds software
- International
- Phase I and II resulted in 27 proposed candidate criteria in laboratory and clinical domains
Recommendations
As reported in the abstract
Pairwise decisions resolved by multicriteria decision analysis (MCDA)
81
Further findings
Premeeting evaluation of 20 representative patients
- Variability in APS assessment
Original publication
Development of the 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria, Phase III‐D Report: Multicriteria Decision Analysis. Arthritis Care Res (Hoboken). Published 30 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →